The D225G genetic variation is increasingly seen as a major virulence factor in human Influenza strains. It works by enabling virus to attach to cells lining the lung rather than the upper respiratory tract.
Lung damage is what puts previously healthy individuals in intensive care on life support.
International trials on efficacy of intravenous "Relenza" (developed by Biota) are in progress. Some reports indicate "miraculous" recovery in critically ill patients.
With Tamiflu resistant strains there is no alternative antiviral to "Relenza" available. There are as yet no reports of long acting "Lani" antiviral (also developed by Biota) being used to treat critically ill influenza patients.
"Relenza" is a life-saver.
Regards Kangaroo1
BTA Price at posting:
80.5¢ Sentiment: Hold Disclosure: Held
